The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results.

Size: px
Start display at page:

Download "The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results."

Transcription

1 The Aptuit Center for Drug Discovery & Development Verona, Italy Uncommon Expertise. Exceptional Results.

2 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable scientific group, comprised of some of the industry s foremost drug discovery and development experts, forms a collaborative team at The Aptuit Center for Drug Discovery & Development in Verona, Italy. They are specialists with uncommon expertise in neuroscience, antibacterial, oncology, cardiovascular, respiratory and other key therapeutic areas. Together, with our other development sites in the US and the UK, these experts stand among Aptuit s vast, global assembly of talented people with Heads for Science and Hearts for Service. Essential throughout the development process is the Project Manager who serves as the client s advocate and ensures exceptional results. Focused on the fastest, most efficient and lowest risk option, Aptuit s Project Managers are highly experienced professionals who fully understand that the client and Aptuit are most effective when working together in a partnership that is flexible, trustworthy and transparent.

3 The Best of Both Worlds: a CRO and an R&D Engine The Aptuit facilities in Verona, Italy, combine the proven efficiency of a Contract Research Organization (CRO) with the established scientific expertise of an accomplished and successful Research and Development engine. When compared to typical CROs, it is significant that the experience of much of the scientific staff has been attained within the pharmaceutical industry, rather than simply for the pharmaceutical industry. Scientists at the facilities have advanced a large number of molecules from early discovery through clinical development with low attrition rates on many target classes. Their expertise in multiple therapeutic areas imparts a strong measure of confidence and credibility for pharmaceutical clients. Working as a highly integrated team, Aptuit scientists take a solution-driven approach, progressing compounds efficiently, expeditiously and economically. GMP authorization for both API and drug manufacturing and testing facilities are in place with regulatory inspections performed by AIFA, the Italian Drug Agency, and the FDA. Preclinical facilities for biological studies are fully GLP certified by the Italian Ministry of Health according to OECD principles. GCP compliance has also been determined for testing of human samples and management of clinical studies. 3

4 4 The Aptuit Center for Drug Discovery & Development Verona, Italy Integrated Knowledge: a unique, dynamic differentiator Integrated Knowledge captures all that is exceptional about The Aptuit Center for Drug Discovery & Development. The term stands for the essence of what clients whether they represent large, multinational companies or emerging biotechs can anticipate as a unique, reliable and consistent advantage when they select Aptuit as their partner. Specifically, Integrated Knowledge represents layer upon layer of the insights and understanding of a collaborative group of multidisciplinary scientific experts and their support teams who routinely have access to the most advanced technologies. The Integrated Knowledge of scientific professionals in Drug Design & Discovery, Preclinical Biosciences, Chemistry, Manufacturing & Control (CMC), and Clinical Sciences is a significant and dynamic Aptuit differentiator. Integrated Knowledge is the driving force in taking the client s molecule through to finished drug product with maximum efficiency.

5 Benefits for both integrated and stand alone services Whether clients choose an Integrated Service Offering or select stand alone services, they experience the Integrated Knowledge of scientists at The Aptuit Center for Drug Discovery & Development, who share an insatiable quest for learning and are able to grasp all the subtleties and implications of the entire picture. Their all-encompassing vision of the process, always in the spirit of sharing their individual knowledge with each other, allows for a deeper, greater understanding of the parameters set forth by the client. Significantly, the broadened perspective of Integrated Knowledge allows for the identification of challenges that may surface later on in the process. Therefore, as the process unfolds, Integrated Knowledge mitigates risks by anticipating potential problems and suggesting preemptive solutions. The Aptuit Integrated Service Offering Target Validation DISCOVERY Services Target To Lead Lead To Candidate Development Services Preclinical Development Clinical Development Computational Chemistry Medicinal Chemistry DMPK & Bioanalysis Structural and Analytical Sciences Pharmacology & Safety Pharmacology API Development & Manufacturing Pharmaceutical development & Manufacturing Toxicology & Pathology Clinical sciences 5

6 6 The Aptuit Center for Drug Discovery & Development Verona, Italy Fully integrated services from a single site The facility s broad range of integrated capabilities includes Drug Design and Discovery, Preclinical Biosciences, Chemistry, Manufacturing and Control (CMC), Clinical Sciences and Integrated Drug Discovery and Development programs. For clients, fully integrated drug discovery and development services from a single site deliver a number of tangible benefits such as reduced timelines, cost effectiveness, elimination of technical or informational transfers and efficiency to provide rapid solutions. Successful processes are in place to advance the client s molecule from discovery to finished product. Drug Design and Discovery Rapid Solutions Reduced Timelines Preclinical Biosciences Integrated Drug Discovery and Development Improved Efficiency Chemistry, Manufacturing and Control Cost Effectiveness Clinical Sciences

7 Experts in overcoming early development challenges The breadth of Aptuit s capabilities in Verona bring added value to clients who are accustomed to dealing with several suppliers. Clients experience convenience, time and cost savings, and an exceptional level of quality performance that is the result of well established collaborative expertise. Among the other notable capabilities available from The Aptuit Center for Drug Discovery & Development are Integrated Non-Human Primate Facilities and Applied Immunology services. A full range of exploratory/ preliminary, regulatory, investigative, customized and fit for purpose studies can be conducted. AAALAC accredited animal facilities and procedures are used. In addition, preclinical development studies of vaccine/viral vector/gene therapy, such as GLP biodistribution and virus shedding, are available. 7

8 8 The Aptuit Center for Drug Discovery & Development Verona, Italy Drug Design & Discovery from Target to Lead to Candidate Aptuit s comprehensive Drug Design & Discovery processes are led by scientists with experience in target identification and validation of preclinical candidate molecules. Core discovery services, available as a fully integrated offering or as stand alone services, include: Computational Chemistry, Medicinal Chemistry, Discovery Biology, Pharmacology, Drug Metabolism and Pharmacokinetics (DMPK), Safety Assessment, and Analytical Discovery Support. In addition, expertise in Toxicology, Pharmaceutical Development and Clinical Sciences capabilities are brought into the process for a truly translational approach. Aptuit can provide Drug Design & Discovery solutions exceeding those normally associated with CRO offerings, providing a versatile range of valueadded business options best suited to individual client needs. Among these unique options are bundled Drug Design & Discovery and Preclinical Biosciences services. The bundled Aptuit offering of these services from a single site delivers integrated capabilities of the highest quality at substantial cost savings.

9 A comprehensive range of Drug Discovery capabilities n Hit Identification: featuring UHit, Aptuit s comprehensive, alternative approach that employs Virtual HTS computational screening through 2D/3D descriptors and structure-based ligandbased de novo design, and Discovery Biology, targeting activity and selectivity screens (affinity and/or functional in recombinant cell lines or native tissue) n Integrated Lead Optimization: an advanced approach that relies on fully integrated research units, multi-factorial optimization and a Fit-for-Purpose strategy n Fast-Follower, Knowledge-Based & Back-up Strategies: innovating new chemistry for existing drugs/scaffolds to improve safety and efficacy profiles n Exploratory Development Assessment: including preliminary Safety and DMPK when there is a low quantity or poor quality of available API n Translational Biology and Safety Strategy: Bench to Bedside research that expedites the translation of scientific discoveries into clinical practice n IP Boost and Generation Engine n Due Diligence and Consulting Hit Identification Integrated Lead Optimization Due Diligence and Consulting DISCOVERY SERVICES Fast-Follower, Knowledge- Based & Back-up Strategies IP Boost and Generation Engine Translational Biology and Safety Strategy Exploratory Development Assessment 9

10 10 The Aptuit Center for Drug Discovery & Development Verona, Italy Preclinical Biosciences, taking a customized approach The Preclinical Biosciences team at The Aptuit Center for Drug Discovery & Development can perform the full spectrum of preclinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client s requirements. From laboratories within the Verona site, they share their expertise in Microbiology, Pharmacology and Safety Pharmacology, Toxicology & Pathology, Drug Metabolism & Pharmacokinetics and Preclinical and Clinical Bioanalysis. The integrated Aptuit team is distinguished by specialized preclinical capabilities. A legacy of success in applied immunology services and in conducting studies for biotherapeutics are notable. Preclinical Biosciences offers expertise in CNS disease, antibacterials, substance abuse, oncology, cardiovascular and other key therapeutic areas.

11 Experienced in the preclinical development of GTMPs The Preclinical Biosciences group is comprised of molecular and cellular biologists, immunologists and toxicology/pathology experts who are dedicated to projects related to the development of Gene Therapy Medicinal Products (GTMPs). The team can perform GLP studies for GTMPs that include integrated parallel toxicology/ pathology, efficacy and biodistribution studies, with flexible study plans to accelerate preclinical development. Before the release of the GTMP, quality tests on produced batches are performed, including: titer determination, pseudotyping identity (for viral vectors), residual DNA contamination, stability studies and transgene identity. A key component of GTMP development is quality control testing, including: Titer determination Pseudotyping identity (for viral vectors) Residual DNA contamination Stability studies Transgene identity 11

12 12 The Aptuit Center for Drug Discovery & Development Verona, Italy CMC Services, all under one roof in Verona Aptuit clients can rely on fully integrated Chemistry, Manufacturing & Control (CMC) services from the Verona site. Well established capabilities in Chemical Development and Manufacturing, Pharmaceutical Development, Analytical and Physical Science and Clinical Supply conjoin to make Aptuit the ideal CMC partner. The seamless integration of drug substance and drug product services, all performed under one roof in Verona, provides clients with a distinctive advantage: every aspect of their project is accomplished by a single, unified, collaborative team. Aptuit s CMC team takes the big picture approach in the development of both drug substance (API) and drug product. The broadened perspective of Integrated Knowledge enables scientists to address early findings that foresee potential issues that might surface later on in the process, avoiding or mitigating the risks of unexpected delays and costs.

13 Complementary Vision, a novel way to deliver services Aptuit has initiated a new way of delivering CMC services, known as Complementary Vision. This harmonized approach encompasses all of the services that precede and follow the CMC profile. Cost efficiency and time saving benefits through the design of the dosage form that best fits the preclinical/ clinical needs are the result of this novel approach. CMC clients can rely on a combination of in silico, in vitro and in vivo services. The results substantiate the design, development and selection of the most effective dosage form for the intended clinical use, throughout the application of biopharmaceutics from early to late development stages. A comprehensive review process is undertaken for generic drugs to meet up-to-date regulatory requirements. Expertise in API development and manufacturing ensures the timely delivery of the required quality of API to support both toxicological and clinical studies. Aptuit also provides the required analytical support, including method development and validation and batch release. Lean Six Sigma business processes are in place, helping to ensure total quality management. 13

14 14 The Aptuit Center for Drug Discovery & Development Verona, Italy Clinical Sciences: early understanding to maximize success From the onset, the Clinical Sciences group can partner with clients in the design of the most efficient clinical plans for the client s compound. And through innovative and custom tailored approaches, clients benefit from an early understanding of their compound s safety and efficacy profile, prior to First In Man studies. It s an advantage that results in valuable time and cost savings. A range of capabilities combine in a rapid decision making process for an early establishment of efficacy, acceptable safety and pharmacokinetic profile. They include the design, implementation and analysis of Positron Emission Tomography (PET) brain studies, human laboratory models, the adoption of advanced methodologies in modeling and simulation and translational medicine strategy.

15 A well established network of collaborative expertise Clinical Sciences experts are skilled in recommending and placing studies with imaging centers that are best suited to client projects. It s Aptuit s expertise in PK analysis and PK/PD correlation that allows for the objective interpretation of the resulting data to best investigate target enhancement in the living brain and to determine the time course. Clinical Science experts physicians, clinical pharmacologists, statisticians, pharmacokineticists, data managers, programmers, and study managers work together in the design, implementation, analysis and interpretation of healthy volunteer and patient studies in multiple therapeutic areas and across clinical phases. An established network of collaborative expertise is in place, with access to multiple Phase I Units and academic/clinical centers. Clients gain added confidence in Aptuit when learning that the Clinical Sciences group has successfully advanced more than 20 NCEs to FIM, conducted 15 Phase II clinical studies eight that have reached Proof of Concept. The group has implemented over 100 Clinical Pharmacology and Experimental Medicine studies. 15

16 16 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit INDiGO, addressing today s challenges A significant solution to overcoming the time and cost challenges of drug development is Aptuit INDiGO. This accelerated development process uses integrated, parallel development tracks to advance API to regulatory submission in as few as 26 weeks. In just 52 weeks, compounds can progress from candidate selection to regulatory submission, a highly desirable alternative to the industry average of 122 weeks. By adding 30 additional weeks, Aptuit INDiGO takes the compound into the clinical phase and provides human safety, tolerability and pharmacokinetics results from First In Man studies. To date, Aptuit s multidisciplinary teams of experts have successfully implemented more than 60 Aptuit INDiGO packages across a wide range of therapeutic areas for small and large molecules, drug product changes, and post FIM and IP extension opportunities. Aptuit INDiGO can be customized to advance your molecule from candidate selection to FIM/POC studies World class preclinical safety/dmpk & solid state chemistry Quality-by-design principles applied in earliest stages Seamless data and knowledge integration throughout project Regulatory documentation preparation & Clinical Sciences Reduced service provider monitoring

17 Accelerated development, real time data When performed at The Aptuit Center for Drug Discovery & Development and other global sites, Aptuit INDiGO addresses other industry challenges by providing an integrated approach. The accelerated process overcomes the negative effects of dealing with multiple outsourcing companies or incurring difficulties created by inefficient handoff between multidisciplinary groups. Aptuit INDiGO also delivers a real time, high quality data package with interpretation in key development areas, not something that is commonly found when clients are working with other CROs. Optimized timelines are achieved by using integrated, parallel development tracks Industry average based on Tufts CSDD analysis: 122 weeks (Compared with Aptuit INDiGO 52 week package) As few as 26 weeks from API availability to Regulatory Submission As few as 52 weeks from Candidate Selection to Regulatory Submission Only 30 additional weeks from Regulatory Submission to FIM study report 17

18 18 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit s global family of world class facilities Aptuit s facilities in Verona have made a substantial contribution to Aptuit s global family of worldwide centers of drug discovery and development. From seven strategically located sites around the world, including a strategic partner in India, Aptuit people serve more than 600 clients. This client base spans small companies that may not maintain in-house technical expertise to multinational companies who turn to The Aptuit Center for Drug Discovery & Development to outsource large, integrated projects. It is significant that Aptuit is involved in 20% of the 10,000 molecules that are under development at any given time. Harrisonville, Missouri West Lafayette, Indiana Oxford, England Glasgow, Scotland Aptuit Corporate Headquarters, Greenwich, Connecticut

19 Specialized capabilities at key locations In addition to providing fully integrated services from its Verona site, Aptuit offers specialized services from other facilities: n SSCI, a division of Aptuit, located in West Lafayette, Indiana, and recognized around the world for its solid state chemistry leadership n Aptuit s Glasgow, Scotland site, known for its sterile fill finish and formulation development for a range of dosage forms n API facilities in the United States and Europe, along with a strategic partner in India, feature strong competencies in API development and manufacture including process R&D, analytical and chemical development, preclinical and clinical supply, high potency APIs and cytotoxics, pilot manufacturing and commercial scale manufacturing Throughout this global enterprise, a synergy of collaborative expertise delivers related services that include consulting services from the industry s foremost regulatory and legal experts. These consummate professionals are among the many Aptuit people at global locations who bring their Heads for Science and Hearts for Service to create a streamlined drug discovery and development process for biotechnology and pharmaceutical innovators. Glasgow, UK Oxford, UK Verona, Italy Greenwich, CT West Lafayette, IN Harrisonville, MO 19

20 The Aptuit Center for Drug Discovery & Development Verona, Italy Via Alessandro Fleming Verona (VR) Italy For information about Aptuit s services, please contact us: in Europe: in the US: us at: expertise@aptuit.com The sculptures featured prominently throughout this brochure can be found in the lobby and building exterior of the Aptuit Verona facility. Created by Novello Finotti and Pino Castagna, they symbolize the felicitous union of the theory and practice of scientific research in the evolution of mankind. Sculpture by Novello Finotti and Pino Castagna, Grande Scorticato by Novello Finotti, APT/BRO/VERONASITE/12/12/V001

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

Pharmacology skills for drug discovery. Why is pharmacology important?

Pharmacology skills for drug discovery. Why is pharmacology important? skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

More information

SERVICES FOR. Devices and Combination Products

SERVICES FOR. Devices and Combination Products SERVICES FOR Devices and Combination Products How to Contact Us U.S. FACILITIES / CLIENT SERVICES St. Paul 2540 Executive Drive St. Paul, MN 55120 FAX 651.675.2005 Atlanta 1265 Kennestone Circle Marietta,

More information

Valentina Gualato, Ph.D. Process Development Scientist

Valentina Gualato, Ph.D. Process Development Scientist COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB

More information

Quality by Design Concept

Quality by Design Concept 3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,

More information

Global regulatory affairs role in the biopharmaceutical industry

Global regulatory affairs role in the biopharmaceutical industry CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global

More information

Dr Alexander Henzing

Dr Alexander Henzing Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander

More information

MSC IN MEDICINAL CHEMISTRY

MSC IN MEDICINAL CHEMISTRY faculty of health and medical sciences university of copenhagen MSC IN MEDICINAL CHEMISTRY det sundhedsvi københavns univer Master s programme at the University of Copenhagen msc in medicinal chemistry

More information

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Call 2014: High throughput screening of therapeutic molecules and rare diseases Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for

More information

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB

More information

DMPK: Experimentation & Data

DMPK: Experimentation & Data DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students

More information

4.1 Objectives of Clinical Trial Assessment

4.1 Objectives of Clinical Trial Assessment L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical

More information

NEW CHEMICAL ENTITIES

NEW CHEMICAL ENTITIES NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

SIPBS Portfolio. 2012-13 Entry

SIPBS Portfolio. 2012-13 Entry SIPBS Portfolio 2012-13 Entry MSc Programmes Existing: MSc Pharmaceutical Analysis MSc Analysis of Medicines (distance learning) MSc Clinical Pharmacy New Programmes just launched for Sept 2012 entry:

More information

PharmD Postdoctoral Fellowship Program

PharmD Postdoctoral Fellowship Program Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the

More information

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD 1 Summary Hypothesis Generation Candidate Development Commercialization Target Identification

More information

Master of Science in Biomedical Sciences

Master of Science in Biomedical Sciences Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

How To Get A Grant From Kinesis

How To Get A Grant From Kinesis - The collaboration initiative to move drug candidates forward Introduction What are we offering? How? Why apply? Terms Background For grant applications and to attract venture capital start-up companies

More information

Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA

Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA PharmaSUG 2014 Paper CP07 Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA ABSTRACT In the biopharmaceutical

More information

Luca Romagnoli, Ph.D. Business Development Manager

Luca Romagnoli, Ph.D. Business Development Manager Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies

More information

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before

More information

BIOTECHNOLOGY OPERATIONS

BIOTECHNOLOGY OPERATIONS BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

Catalent Biologics & Clinical Supplies The SMART Solution

Catalent Biologics & Clinical Supplies The SMART Solution Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)

Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com) M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over

More information

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC

More information

BIOSCIENCES COURSE TITLE AWARD

BIOSCIENCES COURSE TITLE AWARD COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science

Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science Position: Biostatistician Required Experience: At least 5 years This position is responsible for providing broad statistical support in general and biostatistical support specifically, including study

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization

More information

Brand Quality with Asian Advantages

Brand Quality with Asian Advantages Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com

More information

Taking a Leap Toward Global Supply Chain Efficiency

Taking a Leap Toward Global Supply Chain Efficiency Taking a Leap Toward Global Supply Chain Efficiency 2 Taking a Leap Toward Global Supply Chain Efficiency INTRODUCTION PROBLEM STATEMENT Pharmaceutical manufacturers face a number of challenges to produce

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace

More information

Pharmaceutical Sciences

Pharmaceutical Sciences Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences

More information

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your

More information

GMP Pharma BV. Netherlands

GMP Pharma BV. Netherlands GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization

More information

Ph.D Programs at Near East University Faculty of Pharmacy

Ph.D Programs at Near East University Faculty of Pharmacy Ph.D Programs at Near East University Faculty of Pharmacy Ph.D Programs at Near East University, Faculty of Pharmacy NEU Faculty of Pharmacy offers advanced training and education leading toward Ph.D degree.

More information

DZIF-Product Development Unit (PDU)

DZIF-Product Development Unit (PDU) November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Session 6 Clinical Trial Assessment Phase I Clinical Trial L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering

Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering Medical Device Solutions Battelle Applied Research Device Development Clinical Research Sustaining Engineering 0 2 Overview Applied Research Device Development Clinical Research Sustaining Engineering

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for

More information

October 17, 2005. Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892

October 17, 2005. Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892 October 17, 2005 Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892 Dear Dr. Zerhouni: The undersigned nonprofit medical and scientific societies

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL

More information

University-wide Courses/Seminars These 4 courses are offered by the Graduate School:

University-wide Courses/Seminars These 4 courses are offered by the Graduate School: PROGRAMMES OF STUDY Institute of Chinese Medical Sciences PhD Programme AREAS OF STUDY Biomedical Sciences University-wide Courses/Seminars These 4 courses are offered by the Graduate School: GRSC801 Research

More information

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations

More information

PharmaPendium. The definitive source of best-in-class drug information

PharmaPendium. The definitive source of best-in-class drug information Please contact us for more information Americas E-Customer Service 360 Park Avenue South New York, NY 10010-1710 USA Tel: +1 888 615 4500 (+1 212 462 1978, if calling from outside the USA and Canada) Fax:

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

Engineering Nanomedical Systems

Engineering Nanomedical Systems BME 695 November 8, 2011 Engineering Nanomedical Systems Lecture 15 GMP and issues of quality control manufacture of nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor

More information

Extemporaneously Prepared Early Phase Clinical Trial Materials

Extemporaneously Prepared Early Phase Clinical Trial Materials Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development

More information

MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY

MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY Academic Reference Standards of Pharm.-D Program College of Pharmacy-University of Hail May The Major shift in the health-care system

More information

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society

More information

Strategic Benefits of an Online Clinical Data Repository

Strategic Benefits of an Online Clinical Data Repository Strategic Benefits of an Online Clinical Data Repository 5625 Dillard Drive Suite 205 Cary, NC 27518 www.pharsight.com Strategic Benefits of an Online Clinical Data Repository Contents Introduction 2 The

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

Masters Learning mode (Форма обучения)

Masters Learning mode (Форма обучения) Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)

More information

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting - A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,

More information

Course Curriculum for Master Degree in Clinical Pharmacy

Course Curriculum for Master Degree in Clinical Pharmacy Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon

More information

Accreditation of Master of Pharmacy Degrees

Accreditation of Master of Pharmacy Degrees Accreditation of Master of Pharmacy Degrees Interim standards, Sept 2010 Introduction This document sets out the standards against which we, the General Pharmaceutical Council (GPhC), will accredit those

More information

PEOPLE > SCIENCE > SOLUTIONS

PEOPLE > SCIENCE > SOLUTIONS PEOPLE > SCIENCE > SOLUTIONS Our difference Our foundation Our focus ANALYTICAL CHEMISTRY & MATERIALS CHARACTERIZATION EFFICACY (Functional testing) BIOCOMPATIBILITY (in vivo & in vitro toxicology) CLINICAL

More information

How to develop Antibody Drug Conjugates: Bioanalysis Contribution

How to develop Antibody Drug Conjugates: Bioanalysis Contribution How to develop Antibody Drug Conjugates: Bioanalysis Contribution Recommendations and survey results Presenter: Matt Barfield on behalf of the EBF TT43 7th Open Symposium 19 th November 2014 Barcelona

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

Change Management for Virtual Pharmaceutical Firms. Randall Tlachac Molecular and Cellular Therapeutics

Change Management for Virtual Pharmaceutical Firms. Randall Tlachac Molecular and Cellular Therapeutics Change Management for Virtual Pharmaceutical Firms Randall Tlachac Molecular and Cellular Therapeutics Opening Considerations Managing the kinds of changes encountered by and instituted between two organizations

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

BEST PRACTICES RESEARCH

BEST PRACTICES RESEARCH 2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost

More information

EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES

EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES EXPERT REVIEW PANEL PROCEDURE: ADDITIONAL SUPPORT TO PROCUREMENT AGENCIES UNDER EXCEPTIONAL CIRCUMSTANCES Introduction The WHO Prequalification of Medicines Programme (PQP) was established to provide UN

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

ANALYTICAL OUTSOURCING WHY SHOULD YOU OUTSOURCE?

ANALYTICAL OUTSOURCING WHY SHOULD YOU OUTSOURCE? ANALYTICAL OUTSOURCING WHY SHOULD YOU OUTSOURCE? The choice to outsource is a somewhat difficult decision, but it is one that can be both analytically and financially rewarding. By carefully considering

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Triskel: a strategic consulting firm for biopharmaceutical companies

Triskel: a strategic consulting firm for biopharmaceutical companies BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland

More information

SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS

SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS Graduate Programs CELL, MOLECULAR, AND DEVELOPMENTAL BIOLOGY CLINICAL

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

Programme Specification (Undergraduate) Date amended: August 2012

Programme Specification (Undergraduate) Date amended: August 2012 Programme Specification (Undergraduate) Date amended: August 2012 1. Programme Title(s) and UCAS code(s): BSc Biological Sciences C100 BSc Biological Sciences (Biochemistry) C700 BSc Biological Sciences

More information

Introduction. Introducing the Sample Pilot. MAST User Interface and Software. Modular Automated Sampling Technology Platform

Introduction. Introducing the Sample Pilot. MAST User Interface and Software. Modular Automated Sampling Technology Platform We Believe You Deserve Better Technologies to Achieve Your Product Quality Goals Introduction The bioprocessing industry demands a reliable system that transfers bioprocess samples directly from bioreactors

More information

White Paper CLINICAL RESEARCH IN BELGIUM AN INTRODUCTION

White Paper CLINICAL RESEARCH IN BELGIUM AN INTRODUCTION White Paper CLINICAL RESEARCH IN BELGIUM AN INTRODUCTION Table of Contents 1. Introduction... 3 2. Clinical Research Activity in Belgium... 3 3. The Regulatory Landscape in Belgium... 3 4. The Healthcare

More information

Dr.ssa Maria Luisa Nolli CEO

Dr.ssa Maria Luisa Nolli CEO IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

Conditions for Accreditation as (Basic) Pharmacologist

Conditions for Accreditation as (Basic) Pharmacologist NEDERLANDSE VERENIGING VOOR FARMACOLOGIE DUTCH PHARMACOLOGICAL SOCIETY Conditions for Accreditation as (Basic) Pharmacologist 1. Introduction The Dutch Pharmacological Society (DPS) is the organization

More information

Testing Services for Large Molecule Drug Development

Testing Services for Large Molecule Drug Development Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,

More information

An integrated global healthcare company

An integrated global healthcare company An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment

More information

White Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION

White Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION White Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION Table of Contents 1. Healthcare Landscape in Poland... 3 2. Clinical Research Activity in Poland... 3 3. References... 6 4. About the Author... 6

More information

Bachelor of Science in Applied Bioengineering

Bachelor of Science in Applied Bioengineering Bachelor of Science in Applied Bioengineering Applied bioengineering employs scientific and engineering principles to process biological materials from biological agents for provision of goods and related

More information

An Introduction to Genomics and SAS Scientific Discovery Solutions

An Introduction to Genomics and SAS Scientific Discovery Solutions An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!

More information

Future Specialisation for Pharmacists in Industry

Future Specialisation for Pharmacists in Industry Future Specialisation for Pharmacists in Industry JANE NICHOLSON Executive Director European Industrial Pharmacists Group (EIPG) Innovation gap... Cost is now ~ 700-1billion Success Rate 1 in 10,000 By

More information

REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed])

REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed]) REGULATIONS FOR THE DEGREE OF BACHELOR OF PHARMACY IN CHINESE MEDICINE [PART-TIME] (BPharm[ChinMed]) These regulations apply to students admitted to the first year of study in and after the academic year

More information

Smart Asset Management Services

Smart Asset Management Services GE Healthcare Life Sciences Smart Asset Management Services Share our breadth of experience Share our breadth of A solid foundation to build on The biotech and pharmaceutical industries face major challenges

More information

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process

More information